Atrogi AB

11 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Dec 2033

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 24, 2027
The maintenance fee for Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia (US 11,793,774) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,891,212	Screening method, a kit, a method of treatment and a compound for use in a method of treatment In force Ends no later than Dec 16, 2033 · From the USPTO record	In force	Ends no later than Dec 16, 2033	From the USPTO record
US 9,784,726	Screening method, a kit, a method of treatment and a compound for use in a method of treatment In force Term ends Jan 8, 2034 · From the USPTO record	In force	Term ends Jan 8, 2034	From the USPTO record
US 10,288,602	Screening Method, a Kit, A method of Treatment and a Compound for Use in a Method of Treatement In force Term ends Jan 8, 2034 · Medium confidence	In force	Term ends Jan 8, 2034	Medium confidence
US 9,657,348	Method of screening compounds for the treatment of diabetes In force Term ends Jan 13, 2034 · From the USPTO record	In force	Term ends Jan 13, 2034	From the USPTO record
US 11,357,757	Heteroaryl Substituted Beta-Hydroxyethylamines for Use in Treating Hyperglycaemia In force Term ends Sep 13, 2038 · High confidence	In force	Term ends Sep 13, 2038	High confidence
US 11,427,539	Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia In force Term ends Sep 13, 2038 · From the USPTO record	In force	Term ends Sep 13, 2038	From the USPTO record
US 12,280,023	Fluorophenyl Beta-Hydroxyethylamines and Their Use in the Treatment of Hyperglycaemia In force Term ends Sep 13, 2038 · Medium confidence	In force	Term ends Sep 13, 2038	Medium confidence
US 11,648,216	Fluorophenyl Beta-Hydroxyethylamines and Their Use in the Treatment of Hyperglycaemia In force Term ends Apr 19, 2039 · High confidence	In force	Term ends Apr 19, 2039	High confidence
US 11,793,774	Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia In force Term ends Apr 20, 2039 · From the USPTO record	In force	Term ends Apr 20, 2039	From the USPTO record
US 12,036,210	Heteroaryl Substituted Beta-Hydroxyethylamines for Use in Treating Hyperglycaemia In force Term ends Jul 4, 2039 · High confidence	In force	Term ends Jul 4, 2039	High confidence

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 7 no status recorded

List them